iOrganBio
Category: AI in Healthcare
AI-powered platform for consistent, scalable, and intelligent manufacturing of cells and organoids for in vitro modeling and cell therapies iOrganBio was founded in 2024. The company is led by Daniel Delubac. Based in Chapel Hill, North Carolina, USA. Team size: 11-50. Total funding raised: $2 million. Latest round: Seed Round. Key investors include First Star Ventures, IndieBio, Cape Fear BioCapital, 2ndF, Terasaki Institute, Alix Ventures.
- Founded
- 2024
- Headquarters
- Chapel Hill, North Carolina, USA
- Team size
- 11-50
- Total funding
- $2 million
Value proposition
To provide a reproducible and scalable supply of specialized stem-cell-derived products, accelerating disease modeling, regenerative medicine, and drug development through their AI-powered CellForge platform
Products and solutions
CellForge Platform
Unique value
iOrganBio's uniqueness lies in its digital-first approach to cell manufacturing, using a closed-loop process that combines AI with single-cell and multi-omics data to create digital blueprints for each cell type
Target customer
Pharmaceutical companies, biotech companies, and research institutions involved in drug development, disease modeling, and regenerative medicine
Industries served
Biotechnology, Pharmaceuticals, Healthcare
Technology advantage
The core technological advantage is the CellForge platform, which digitally automates cell manufacturing using a proprietary Functional Human Cell Atlas built from single-cell and multi-omics data that provides digital blueprints for each cell type
How they differentiate
iOrganBio differentiates itself through its AI-powered CellForge platform, which automates and scales the manufacturing of human cells and organoids using a proprietary Functional Human Cell Atlas for higher reproducibility and precision
Main competitors
OrganaBio, Cellecta, StemCell Technologies
Key partnerships
First Star Ventures, IndieBio, Cape Fear BioCapital, 2ndF, Terasaki Institute, Alix Ventures
Major milestones
Successfully raised $2 million in seed funding, Launched from stealth mode, Introduced proprietary CellForge platform
Growth metrics
Not publicly available
Market positioning
Early-stage startup positioned at the intersection of regenerative medicine, AI, and biotechnology, targeting the emerging market for scalable, high-quality human cell manufacturing
Geographic focus
United States, particularly the Research Triangle area and broader North American market
Patents and IP
Information not publicly available
About Daniel Delubac
Formerly of Guardant Health, Freenome, and Chemify; COO/CTO of precision oncology company 2020-2023; Started career at Counsyl building automated clinical-grade NGS systems
Official website: https://iorgan.bio/